CryoPort (NASDAQ:CYRX) Releases Earnings Results, Misses Expectations By $0.01 EPS

CryoPort (NASDAQ:CYRX) issued its earnings results on Thursday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01), Zacks reports. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.13%. The firm had revenue of $48.97 million during the quarter, compared to analysts’ expectations of $48.18 million.

Here are the key takeaways from CryoPort’s conference call:

• Revenue reached $49 million in the second quarter, with Life Sciences Services revenue up 15% year over year, commercial cell and gene therapy support revenue up 9%, and clinical-trial support revenue up 12%.
• Cryoport achieved positive adjusted EBITDA of $400,000, a $1.3 million year-over-year improvement, and generated approximately $5 million of operating cash flow in the first half, supporting management’s path toward sustainable profitability.
• The company’s pipeline remains broad, with 779 clinical trials supported globally, 22 commercial cell and gene therapies, and expectations for 11 potential BLA/MAA filings, five new therapy approvals, and one label or geographic expansion during the remainder of 2026.
• Cryoport reaffirmed its 2026 continuing-operations revenue guidance of $192 million to $196 million rather than raising it, citing geopolitical and macroeconomic uncertainty despite strong underlying demand.
• New growth initiatives—including IntegriCell cryopreservation services, the Fusion 811 freezer, China-based manufacturing, and new supply-chain facilities in Paris and Santa Ana—are expected to expand future capacity, although IntegriCell is not expected to contribute significantly to 2026 revenue.

CryoPort Stock Performance

Shares of NASDAQ CYRX opened at $15.12 on Friday. The company’s fifty day moving average price is $15.49 and its 200 day moving average price is $11.92. CryoPort has a 1 year low of $7.51 and a 1 year high of $16.89. The company has a market capitalization of $762.08 million, a PE ratio of -16.80 and a beta of 1.89.

Insider Buying and Selling at CryoPort

In other news, insider Edward J. Zecchini sold 33,600 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $14.47, for a total transaction of $486,192.00. Following the sale, the insider directly owned 109,719 shares in the company, valued at $1,587,633.93. This trade represents a 23.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert Stefanovich sold 169,427 shares of CryoPort stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $16.27, for a total value of $2,756,577.29. Following the completion of the transaction, the chief financial officer owned 109,850 shares of the company’s stock, valued at approximately $1,787,259.50. This represents a 60.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 227,641 shares of company stock valued at $3,622,515. Corporate insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On CryoPort

A number of hedge funds have recently bought and sold shares of CYRX. LPL Financial LLC lifted its stake in shares of CryoPort by 6.6% in the 4th quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock valued at $224,000 after purchasing an additional 1,433 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of CryoPort by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after purchasing an additional 1,557 shares during the last quarter. State of Wyoming increased its position in shares of CryoPort by 30.2% during the 2nd quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after purchasing an additional 3,301 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of CryoPort by 55.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock worth $113,000 after purchasing an additional 4,225 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after buying an additional 4,375 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

Analysts Set New Price Targets

CYRX has been the subject of several research reports. Guggenheim lifted their price objective on shares of CryoPort from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Friday. Needham & Company LLC raised their target price on shares of CryoPort from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday. KeyCorp upped their price target on shares of CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Roth Capital reiterated a “buy” rating and set a $21.00 price objective on shares of CryoPort in a research note on Friday. Finally, BTIG Research upped their target price on CryoPort from $17.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.